These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 18803648)

  • 21. Resting SPECT-neuropsychology correlation in very mild Alzheimer's disease.
    Nobili F; Brugnolo A; Calvini P; Copello F; De Leo C; Girtler N; Morbelli S; Piccardo A; Vitali P; Rodriguez G
    Clin Neurophysiol; 2005 Feb; 116(2):364-75. PubMed ID: 15661114
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Two distinct pathological substrates associated with MMSE-pentagons item deficit in DLB and AD.
    Beretta L; Caminiti SP; Santangelo R; Magnani G; Ferrari-Pellegrini F; Caffarra P; Perani D
    Neuropsychologia; 2019 Oct; 133():107174. PubMed ID: 31446008
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Combination of 18F-FDG PET and cerebrospinal fluid biomarkers as a better predictor of the progression to Alzheimer's disease in mild cognitive impairment patients.
    Choo IH; Ni R; Schöll M; Wall A; Almkvist O; Nordberg A
    J Alzheimers Dis; 2013; 33(4):929-39. PubMed ID: 23047371
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of rCBF (SPECT), CSF tau, and cognitive function in patients with dementia of the Alzheimer's type, other types of dementia, and control subjects.
    Tsolaki M; Sakka V; Gerasimou G; Dimacopoulos N; Chatzizisi O; Fountoulakis KN; Kyriazis G; Papanastasiou J; Kazis A
    Am J Alzheimers Dis Other Demen; 2001; 16(1):21-31. PubMed ID: 11416945
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The relationship between CSF biomarkers and cerebral metabolism in early-onset Alzheimer's disease.
    Jaillard A; Vanhoutte M; Maureille A; Schraen S; Skrobala E; Delbeuck X; Rollin-Sillaire A; Pasquier F; Bombois S; Semah F
    Eur J Nucl Med Mol Imaging; 2019 Feb; 46(2):324-333. PubMed ID: 30155553
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CSF phosporylated TAU protein levels correlate with cerebral glucose metabolism assessed with PET in Alzheimer's disease.
    Ceravolo R; Borghetti D; Kiferle L; Tognoni G; Giorgetti A; Neglia D; Sassi N; Frosini D; Rossi C; Petrozzi L; Siciliano G; Murri L
    Brain Res Bull; 2008 May; 76(1-2):80-4. PubMed ID: 18395614
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Measurement of regional cerebral metabolism rate of glucose in patients with Alzheimer's disease in different levels of severity].
    Xiao SF; Cao QY; Xue HB; Liu YC; Zuo CT; Jiang KD; Zhang MY
    Zhonghua Yi Xue Za Zhi; 2005 Nov; 85(42):2975-9. PubMed ID: 16324383
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The role of epsilon phenotype in brain glucose consumption in Alzheimer's disease.
    Ricci M; Chiaravalloti A; Martorana A; Koch G; De Lucia V; Barbagallo G; Schillaci O
    Ann Nucl Med; 2020 Apr; 34(4):254-262. PubMed ID: 32016694
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Markers of Alzheimer's disease in a population attending a memory clinic.
    Frisoni GB; Prestia A; Zanetti O; Galluzzi S; Romano M; Cotelli M; Gennarelli M; Binetti G; Bocchio L; Paghera B; Amicucci G; Bonetti M; Benussi L; Ghidoni R; Geroldi C
    Alzheimers Dement; 2009 Jul; 5(4):307-17. PubMed ID: 19560101
    [TBL] [Abstract][Full Text] [Related]  

  • 30. High tau levels in cerebrospinal fluid predict rapid decline and increased dementia mortality in Alzheimer's disease.
    Degerman Gunnarsson M; Lannfelt L; Ingelsson M; Basun H; Kilander L
    Dement Geriatr Cogn Disord; 2014; 37(3-4):196-206. PubMed ID: 24157938
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Correlations between Alzheimer's Disease Cerebrospinal Fluid Biomarkers and Cerebral Glucose Metabolism after 12 Months of Phenserine Treatment.
    Nordberg A; Kadir A; Andreasen N; Almkvist O; Wall A; Långström B; Zetterberg H
    J Alzheimers Dis; 2015; 47(3):691-704. PubMed ID: 26401704
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Bihemispheric cerebral FDG PET correlates of cognitive dysfunction as assessed by the CERAD in Alzheimer's disease.
    Schönknecht OD; Hunt A; Toro P; Guenther T; Henze M; Haberkorn U; Schröder J
    Clin EEG Neurosci; 2011 Apr; 42(2):71-6. PubMed ID: 21675596
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.
    Visser PJ; Verhey F; Knol DL; Scheltens P; Wahlund LO; Freund-Levi Y; Tsolaki M; Minthon L; Wallin AK; Hampel H; Bürger K; Pirttila T; Soininen H; Rikkert MO; Verbeek MM; Spiru L; Blennow K
    Lancet Neurol; 2009 Jul; 8(7):619-27. PubMed ID: 19523877
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High PIB retention in Alzheimer's disease is an early event with complex relationship with CSF biomarkers and functional parameters.
    Forsberg A; Almkvist O; Engler H; Wall A; Långström B; Nordberg A
    Curr Alzheimer Res; 2010 Feb; 7(1):56-66. PubMed ID: 20205671
    [TBL] [Abstract][Full Text] [Related]  

  • 35. CSF biomarkers in relationship to cognitive profiles in Alzheimer disease.
    van der Vlies AE; Verwey NA; Bouwman FH; Blankenstein MA; Klein M; Scheltens P; van der Flier WM
    Neurology; 2009 Mar; 72(12):1056-61. PubMed ID: 19307538
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.
    Chiotis K; Saint-Aubert L; Rodriguez-Vieitez E; Leuzy A; Almkvist O; Savitcheva I; Jonasson M; Lubberink M; Wall A; Antoni G; Nordberg A
    Mol Psychiatry; 2018 Jul; 23(7):1666-1673. PubMed ID: 28507319
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hypothalamic dysfunction is related to sleep impairment and CSF biomarkers in Alzheimer's disease.
    Liguori C; Chiaravalloti A; Nuccetelli M; Izzi F; Sancesario G; Cimini A; Bernardini S; Schillaci O; Mercuri NB; Fabio P
    J Neurol; 2017 Nov; 264(11):2215-2223. PubMed ID: 28900724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tau positron emission tomography using [
    Kang JM; Lee SY; Seo S; Jeong HJ; Woo SH; Lee H; Lee YB; Yeon BK; Shin DH; Park KH; Kang H; Okamura N; Furumoto S; Yanai K; Villemagne VL; Seong JK; Na DL; Ido T; Cho J; Lee KM; Noh Y
    Neurobiol Aging; 2017 Nov; 59():210-219. PubMed ID: 28890300
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Concordance between brain
    Rubí S; Noguera A; Tarongí S; Oporto M; García A; Vico H; Espino A; Picado MJ; Mas A; Peña C; Amer G
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2018; 37(1):3-8. PubMed ID: 28645685
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Mattsson N; Schöll M; Strandberg O; Smith R; Palmqvist S; Insel PS; Hägerström D; Ohlsson T; Zetterberg H; Jögi J; Blennow K; Hansson O
    EMBO Mol Med; 2017 Sep; 9(9):1212-1223. PubMed ID: 28743782
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.